Immunome (IMNM) Financial Statements & Analysis

Immunome Income Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Immunome, Inc. income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018
Revenue & Gross Profit
Revenue	6.94	9.04	14.02	0.00	0.00	0.00	0.00	0.00
Cost of Revenue	2.96	129.54	0.00	23.11	0.00	0.76	0.62	0.52
Gross Profit	3.99	9.04	14.02	-23.11	0.00	-0.76	-0.62	-0.52
Operating Expenses
Research & Development	174.33	281.89	23.09	23.27	14.11	6.73	8.82	6.88
Selling, General & Administrative	43.77	32.96	19.66	13.79	11.09	4.78	1.53	0.87
Operating Expenses	218.10	314.84	123.55	36.90	25.20	11.51	10.35	7.74
Operating Income	-214.11	-305.80	-109.53	-36.90	-25.20	-12.26	-10.35	-7.74
Other Income/Expense
Interest Income	11.72	12.84	2.72	0.01	-0.01	0.00	0.01	0.04
Interest Expense	0.00	0.00	0.00	0.01	0.01	0.04	0.11	0.14
Other Income/Expense	1.72	12.84	2.72	0.01	0.50	-5.58	-0.10	-0.10
Income
Income Before Tax	-212.39	-292.96	-106.81	-36.90	-24.71	-17.84	-10.44	-7.85
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.04
Net Income	-212.39	-292.96	-106.81	-37.52	-24.71	-17.84	-10.55	-7.85
Net Income - Continuous Operations	-212.39	-292.96	-106.81	-36.90	-24.71	-17.84	-10.55	-7.85
Net Income - Discontinued Operations	-	-	-	-	-	-	-	-
EBITDA	-209.44	-151.89	-28.00	-36.48	-24.45	-17.04	-9.72	-7.18
EBIT	-214.11	-153.46	-28.73	-36.90	-25.20	-12.26	-	-
Depreciation & Amortization	2.96	1.57	0.73	0.42	0.76	0.76	0.62	0.52
Earnings Per Share
Basic EPS	-2.00	-5.00	-5.00	-3.00	-2.00	-2.00	-2.00	-7.00
Diluted EPS	-2.00	-5.00	-5.00	-3.00	-2.00	-2.00	-2.00	-7.00
Basic Shares Outstanding	87.35	58.64	19.84	12.13	11.54	10.11	5.74	1.09
Diluted Shares Outstanding	87.35	58.64	19.84	12.13	11.54	10.11	5.74	1.09

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Immunome Financial Statements

What was Immunome's revenue in fiscal 2025?

Immunome reported revenue of $6.94M in fiscal 2025 (fiscal year ended Dec 31, 2025). That was down 23.2% from $9.04M a year earlier.

Is Immunome profitable?

No. Immunome reported a net loss of $212.39M in fiscal 2025. In fiscal 2024 it lost $292.96M.

What is Immunome's operating margin?

Immunome's operating income was −$214.11M on revenue of $6.94M in fiscal 2025, an operating margin of -3084.8%, compared with -3382.4% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition